TROPION Breast Respond in 1L TNBC

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
There are no real-world data available on the effectiveness and safety of Dato-DXd in adult patients with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy. This NIS will investigate the effectiveness of Dato-DXd, the demographic and clinical characteristics of the patients, and treatment patterns.
Epistemonikos ID: 3445917c8d673a2281d70195ea8f8f27e3234b38
First added on: Oct 10, 2026